• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Mirati - oncology?

Quote
























Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)


https://finance.yahoo.com/news/analyst-forecasts-just-became-more-121948059.html


One thing we could say about the analysts on Mirati Therapeutics, Inc. (NASDAQ:MRTX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After this downgrade, Mirati Therapeutics' 16 analysts are now forecasting revenues of US$53m in 2023. This would be a huge 330% improvement in sales compared to the last 12 months. Per-share losses are expected to creep up to US$13.78. Yet before this consensus update, the analysts had been forecasting revenues of US$74m and losses of US$13.68 per share in 2023. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.
 




anonymous said:
Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)


https://finance.yahoo.com/news/analyst-forecasts-just-became-more-121948059.html


One thing we could say about the analysts on Mirati Therapeutics, Inc. (NASDAQ:MRTX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After this downgrade, Mirati Therapeutics' 16 analysts are now forecasting revenues of US$53m in 2023. This would be a huge 330% improvement in sales compared to the last 12 months. Per-share losses are expected to creep up to US$13.78. Yet before this consensus update, the analysts had been forecasting revenues of US$74m and losses of US$13.68 per share in 2023. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.
Click to expand...

Meek must go.
 




These insiders were all selling up in Jan and your telling me there is nothing to see here.
David Meek
Chief Executive Officer, Director
Laurie D. Stelzer
Chief Financial Officer
Alan Sandler
Executive Vice President, Chief Medical Officer
James G. Christensen
Chief Scientific Officer
Benjamin J. Hickey
Chief Commercial Officer
Bruce L. A. Carter
Independent Director
Julie M. Cherrington
Independent Director
Aaron I. Davis
Independent Director
Henry J. Fuchs
Independent Director
 




anonymous said:
These insiders were all selling up in Jan and your telling me there is nothing to see here.
David Meek
Chief Executive Officer, Director
Laurie D. Stelzer
Chief Financial Officer
Alan Sandler
Executive Vice President, Chief Medical Officer
James G. Christensen
Chief Scientific Officer
Benjamin J. Hickey
Chief Commercial Officer
Bruce L. A. Carter
Independent Director
Julie M. Cherrington
Independent Director
Aaron I. Davis
Independent Director
Henry J. Fuchs
Independent Director
Click to expand...

Meek’s a criminal. Always has been.
 












Bill Trebesky must go.
He does not understand CMC. All he does is just move his hands around and talk process bull $@#t when he avoids the science.

I cannot stand him in charge of our department. He’s also racist.
He told someone they were born doing what they are doing. Who even say that ?
He needs to be let go now.
 




anonymous said:
Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)


https://finance.yahoo.com/news/analyst-forecasts-just-became-more-121948059.html


One thing we could say about the analysts on Mirati Therapeutics, Inc. (NASDAQ:MRTX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After this downgrade, Mirati Therapeutics' 16 analysts are now forecasting revenues of US$53m in 2023. This would be a huge 330% improvement in sales compared to the last 12 months. Per-share losses are expected to creep up to US$13.78. Yet before this consensus update, the analysts had been forecasting revenues of US$74m and losses of US$13.68 per share in 2023. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.
Click to expand...

Meek is the killer of companies
 








LOL, there are some seriously insecure and angry idiots on this board.

Making fun of people’s weight, calling them racist, accusing them of infidelity with their coworkers, claiming the CEO wears a toupee? Really? Did you lose money on your Fergene investment? Nobody cares. Not getting enough attention for your scientific achievements? Blame your mommy and daddy for not loving you enough. Get rejected by KC or wish you had her job? Don’t be mad at our CCO because he’s a player and you are not. Losing your hair? Buy that spray on s$&t they sell on the internet. Move on with your lives.

Pathetic little keyboard warriors.
 




anonymous said:
LOL, there are some seriously insecure and angry idiots on this board.

Making fun of people’s weight, calling them racist, accusing them of infidelity with their coworkers, claiming the CEO wears a toupee? Really? Did you lose money on your Fergene investment? Nobody cares. Not getting enough attention for your scientific achievements? Blame your mommy and daddy for not loving you enough. Get rejected by KC or wish you had her job? Don’t be mad at our CCO because he’s a player and you are not. Losing your hair? Buy that spray on s$&t they sell on the internet. Move on with your lives.

Pathetic little keyboard warriors.
Click to expand...


Awe did you get your feelings hurt? All the criticisms, like it or not, are steeped in facts. None of which are a good look for the afore mentioned reprobates.

Nice try at deflecting the truth, a fairly common move for insecure narcissists who get called out on their crap.
 








Amen. Many leaders don’t put up with BS or drama and it’s hilarious to see the people who are fired or told they aren’t cutting it make up stories and broadcast as if they are truth.



anonymous said:
LOL, there are some seriously insecure and angry idiots on this board.

Making fun of people’s weight, calling them racist, accusing them of infidelity with their coworkers, claiming the CEO wears a toupee? Really? Did you lose money on your Fergene investment? Nobody cares. Not getting enough attention for your scientific achievements? Blame your mommy and daddy for not loving you enough. Get rejected by KC or wish you had her job? Don’t be mad at our CCO because he’s a player and you are not. Losing your hair? Buy that spray on s$&t they sell on the internet. Move on with your lives.

Pathetic little keyboard warriors.
Click to expand...
 








Top Bottom
Back
Quote